Diamyd Medical is a Swedish diabetes company developing precision medicine therapies for the prevention and treatment of autoimmune diabetes.
The investigational flagship product Diamyd® is a disease-modifying antigen-specific immunotherapy for the preservation of endogenous insulin production that has Orphan Drug Designation in the U.S. and has been granted Fast Track designation by the U.S. FDA.
DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset Type 1 Diabetes in eight European countries and in the U.S.
Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.
Company Details
- Employees
- 53
- Address
- Kungsgatan 29, Stockholm,se-111 56,sweden
- Phone
- +46 8 661 00 26
- in****@****myd.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- diamyd.com
- Keywords
- Autoimune Diabetes (Type 1 Diabetes and LADA), Pre-clinical and Clinical Development, Development of Combination Therapies for the Treatment of Autoimmune Diabetes, Preserving Beta Cell Function, Pharmaceutical Development, Targeted Immunotherapy.
- HQ
- Stockholm
Diamyd Medical Questions
Diamyd Medical's helpline number is +46 8 661 00 26
Diamyd Medical's website is diamyd.com
Diamyd Medical's LinkedIn profile is https://se.linkedin.com/company/diamyd-medical
Diamyd Medical has
53 employees.
View email and phone details for 53
employees at Diamyd Medical.
Diamyd Medical's industry is
Pharmaceutical Manufacturing
Diamyd Medical's support email address is info@diamyd.com
Diamyd Medical's categories are Pharmaceutical Manufacturing
